Blood-Based Lung Cancer Assay Matches CT Sensitivity in NLST Evaluation
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.
Biomarkers in midlife adults without dementia may be linked to the earliest signs of waning cognition, researchers found.
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
Results from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
The facility will support the clinical validation of diagnostic kits that provide results via a mobile app without the need for laboratory processing.
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
As diabetes testing evolves, labs are seeing growing interest in earlier screening, additional biomarkers, and tools that can support more preventive care.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
VolitionRx reports its lateral flow prototype can detect nucleosomes in finger-prick blood samples from sepsis patients, enabling rapid, point-of-care testing outside centralized labs, according to company data.